Adjuvant therapy for ER+ breast cancer hinges on tumor size, lymph node involvement, and patient preferences, with hormone therapy or chemotherapy as options. It reduces local and distant recurrence risk. This evidence concerns the gene ESR1 and breast carcinoma.